FIT-(BCMA+CD19)-CAR-T Cells in Recurrent/Refractory Autoimmune Diseases Patients.

Summary

This study is a single-center, open-label, single-dose exploration clinical trial for treating patients with partially relapsed/refractory autoimmune diseases by infusing FIT-(BCMA+CD19)-CAR-T cells after pre-treatment with cleansing therapy. In this study phase, a traditional "3+3" trial design is employed for dose escalation.

Timeline

Start

2025-09-25

Primary completion

2025-11-07

Completion

2041-11-30

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment is suspended to address regulatory requirements. Follow-up of currently enrolled participants continues as planned.”

Drugs

Indications